Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595

COLOPLAST A/S (COLO B)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 02/19 11:07:30 am
521.3 DKK   -0.29%
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares ri..
RE
02/07COLOPLAST A/S : acquires IncoCare Gunhild Vieler GmbH
AQ
02/01COLOPLAST A/S : Insider tradings
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Coloplast A/S : ConvaTec beats low full-year expectations, shares rise

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/15/2018 | 10:49am CET

(Reuters) - British medical devices maker ConvaTec (>> ConvaTec Group) posted better than expected 2017 profit and revenue on Thursday after supply chain problems that it said have now been resolved, lifting its share price by nearly 7 percent.

(Reuters) - British medical devices maker ConvaTec (>> ConvaTec Group) posted better than expected 2017 profit and revenue on Thursday after supply chain problems that it said have now been resolved, lifting its share price by nearly 7 percent.

ConvaTec, which makes catheters and colostomy bags, said adjusted operating profit fell 3.3 percent to $456.8 million(324.62 million pounds), beating analyst expectations of $347.1 million, according to data compiled by Thomson Reuters.

Shares in the company rose 6.9 percent to 211 pence by 0905 GMT.

The company had been hit by logistics problems, including hurricanes disrupting shipping lanes in the Caribbean and the shifting of its Ostomy Care manufacturing operation from the United States to the Dominican Republic.

The supply delays prompted the company to lower its 2017 revenue growth forecast in October to 1-2 percent from more than 4 percent.

Chief Executive Paul Moraviec told Reuters that the results were not what he wanted to be presenting on Thursday because of the setbacks last year but added that 2018 would be a year of stabilisation.

    "We have fully bottomed out all the issues we experienced last year and we are very clear on the underlying reasons. We are getting on now with everything we need to do to get back on track," he said.

However, the company said it expected the impact from back orders and lost orders at its Ostomy Care division to persist in the first half of 2018.

"Performance in the fourth quarter was well ahead of re-set expectations, suggesting the supply disruption issues have not been as bad as feared," Bernstein analysts said.

ConvaTec said it was targeting medium-term revenue growth in line with the market, with momentum returning through 2018.

"Expectation that they will only reach market revenue growth in the medium-term is a disappointment," the Bernstein analysts added, while Peel Hunt analysts described the 2018 outlook as a "modest miss" but said there could be some "relief rally" for the stock.

The company's closest rival Coloplast (>> Coloplast A/S) this month posted weaker than expected quarterly revenue for the fourth time in a row.

ConvaTec's Organic revenue rose 2.3 percent to $1.76 billion, slightly above its lowered guidance and compared with analyst expectations of $1.74 billion.

(Reporting by Justin George Varghese in Bengaluru and Paul Sandle in London; Editing by Gopakumar Warrier and David Goodman)

By Justin George Varghese and Paul Sandle

Stocks treated in this article : Coloplast A/S, ConvaTec Group
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COLOPLAST A/S
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares rise
RE
02/08COLOPLAST A/S : Patent Issued for Adhesive Dressing (USPTO 9877874)
AQ
02/08COLOPLAST A/S : Patent Issued for Surgical Tool and System Adapted to Place a Cu..
AQ
02/08COLOPLAST A/S : Patent Issued for Method of Using a Grooved Dilator and Implanti..
AQ
02/07COLOPLAST A/S : acquires IncoCare Gunhild Vieler GmbH
AQ
02/01COLOPLAST A/S : Insider tradings
AQ
02/01COLOPLAST A/S : delivers solid Q1 interim results and continues to take market s..
PU
01/22COLOPLAST A/S : Allocation of Share Options
AQ
01/10COLOPLAST A/S : Announcement no. 01/2018 - Coloplast completes acquisition of SA..
AQ
2017COLOPLAST A/S : Patent Issued for Method of Implanting a Penile Prosthetic (USPT..
AQ
More news
News from SeekingAlpha
02/01Coloplast ASB 2018 Q2 - Results - Earnings Call Slides 
02/01Coloplast ASB reports Q1 results 
2017Coloplast (CLPBF) Presents At Berenberg European Corporate Conference - Slide.. 
2017Coloplast (CLPBY) Presents At DbAccess Pharmaceutical & Healthcare Corporate .. 
2017Coloplast AS ADR 2017 Q4 - Results - Earnings Call Slides 
Financials ( DKK)
Sales 2018 16 464 M
EBIT 2018 5 143 M
Net income 2018 3 920 M
Debt 2018 1 315 M
Yield 2018 2,88%
P/E ratio 2018 27,99
P/E ratio 2019 25,97
EV / Sales 2018 6,37x
EV / Sales 2019 5,90x
Capitalization 104 B
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | 4-Traders
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 504  DKK
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Lars Søren Rasmussen President & Chief Executive Officer
Michael Pram Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Oliver Johansen Senior VP-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST A/S3.87%17 090
HENRY SCHEIN-2.08%10 733
CANTEL MEDICAL CORP.9.44%4 707
AMPLIFON SPA6.07%3 866
PATTERSON COMPANIES-14.20%2 940
MERIT MEDICAL SYSTEMS, INC.0.35%2 176